Loading clinical trials...
Loading clinical trials...
Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients
Conditions
Interventions
BIM 23A760
Locations
23
United States
Pituitary Center
Los Angeles, California, United States
Massachusetts General Hospital / Neuroendocrine Unit
Boston, Massachusetts, United States
Oregon University, Dept. of Endocrinology and Neurosurgery
Portland, Oregon, United States
UZ Leuven
Leuven, Belgium
Centre Hospitalier Universitaire de Liège
Liège, Belgium
Hospital Universitário Clementino Fraga Filho
Rio de Janeiro, Brazil
Start Date
October 1, 2009
Primary Completion Date
February 1, 2011
Completion Date
February 1, 2011
Last Updated
November 22, 2019
NCT00001595
NCT04837040
NCT04125836
NCT06253897
NCT02611336
NCT05184231
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions